Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma

Clinica Chimica Acta

Volumn 463, Issue , 2016, Pages 39-44

  Sauzay, Chloé ^a,b   Petit, Alexandra ^a   Bourgeois, Anne Marie ^a   Barbare, Jean Claude ^c   Chauffert, Bruno ^a   Galmiche, Antoine ^a,b   Houessinon, Aline ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c Cancéropôle Nord Ouest   (France)

Author keywords

Alpha foetoprotein; Hepatocellular carcinoma; Tumour proteostasis; Unfolded Protein Response

Indexed keywords

ALPHA FETOPROTEIN; SORAFENIB; TUMOR MARKER;

CANCER RESEARCH; CANCER THERAPY; DISEASE MARKER; FOLLOW UP; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN STRUCTURE; REVIEW; UNFOLDED PROTEIN RESPONSE; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; METABOLISM;

ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS;

EID: 84991627855     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.10.006     Document Type: Review

References (60)

1. [1] Terentiev, A.A., Moldogazieva, N.T., Alpha-fetoprotein: a renaissance. Tumour Biol. 34 (2013), 2075–2091, 10.1007/s13277-013-0904-y.
2. [2] Gabant, P., Forrester, L., Nichols, J., Van Reeth, T., De Mees, C., Pajack, B., Watt, A., Smitz, J., Alexandre, H., Szpirer, C., Szpirer, J., Alpha-fetoprotein, the major fetal serum protein, is not essential for embryonic development but is required for female fertility. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 12865–12870, 10.1073/pnas.202215399.
3. [3] Bakker, J., Mees, C.D., Douhard, Q., Balthazart, J., Gabant, P., Szpirer, J., Szpirer, C., Alpha-fetoprotein protects the developing female mouse brain from masculinization and defeminization by estrogens. Nat. Neurosci. 9 (2006), 220–226, 10.1038/nn1624.
4. [4] Peterson, M.L., Ma, C., Spear, B.T., Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer. Semin. Cancer Biol. 21 (2011), 21–27, 10.1016/j.semcancer.2011.01.001.
5. [5] Kajiyama, Y., Tian, J., Locker, J., Regulation of alpha-fetoprotein expression by Nkx2.8. Mol. Cell. Biol. 22 (2002), 6122–6130.
6. [6] Xie, Z., Zhang, H., Tsai, W., Zhang, Y., Du, Y., Zhong, J., Szpirer, C., Zhu, M., Cao, X., Barton, M.C., Grusby, M.J., Zhang, W.J., Zinc finger protein ZBTB20 is a key repressor of alpha-fetoprotein gene transcription in liver. Proc. Natl. Acad. Sci. 105 (2008), 10859–10864, 10.1073/pnas.0800647105.
7. [7] Zhang, H., Cao, D., Zhou, L., Zhang, Y., Guo, X., Li, H., Chen, Y., Spear, B.T., Wu, J., Xie, Z., Zhang, W., ZBTB20 is a sequence-specific transcriptional repressor of alpha-fetoprotein gene. Sci. Rep., 5, 2015, 11979.
8. [8] Nakao, K., Ichikawa, T., Recent topics on α-fetoprotein. Hepatol. Res. 43 (2013), 820–825, 10.1111/hepr.12052.
9. [9] Cui, R., Nguyen, T.T., Taube, J.H., Stratton, S.A., Feuerman, M.H., Barton, M.C., Family members p53 and p73 act together in chromatin modification and direct repression of α-fetoprotein transcription. J. Biol. Chem. 280 (2005), 39152–39160, 10.1074/jbc.M504655200.
10. [10] Kojima, K., Takata, A., Vadnais, C., Otsuka, M., Yoshikawa, T., Akanuma, M., Kondo, Y., Kang, Y.J., Kishikawa, T., Kato, N., Xie, Z., Zhang, W.J., Yoshida, H., Omata, M., Nepveu, A., Koike, K., MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat. Commun., 2, 2011, 338, 10.1038/ncomms1345.
11. [11] Gao, R., Cai, C., Gan, J., Yang, X., Shuang, Z., Liu, M., Li, S., Tang, H., miR-1236 down-regulates alpha-fetoprotein, thus causing PTEN accumulation, which inhibits the PI3K/Akt pathway and malignant phenotype in hepatoma cells. Oncotarget 6 (2015), 6014–6028, 10.18632/oncotarget.3338.
12. [12] Chen, L., Wei, W., Qiuyue, J., Ruimin, W., Hu, W., Relationship between expression of the human alpha-fetoprotein gene and DNA methylation status of the promoter region. Chin. J. Clin. Oncol. 3 (2006), 364–369.
13. [13] Lu, T., Sun, H., Lv, J., Yang, M.F., Zhang, F., Qian, Y., Dong, X.J., EZH2 suppresses hepatocellular differentiation of mouse bone marrow mesenchymal stem cells. Genet. Mol. Res. 13 (2014), 2231–2239, 10.4238/2014.March.31.3.
14. [14] Forner, A., Llovet, J.M., Bruix, J., Hepatocellular carcinoma. Lancet 379 (2012), 1245–1255.
15. [15] Bruix, J., Reig, M., Sherman, M., Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150 (2016), 835–853, 10.1053/j.gastro.2015.12.041.
16. [16] Song, P.-P., Xia, J.-F., Inagaki, Y., Hasegawa, K., Sakamoto, Y., Kokudo, N., Tang, W., Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J. Gastroenterol. 22 (2016), 262–274, 10.3748/wjg.v22.i1.262.
17. [17] Schieving, J.H., de Vries, M., van Vugt, J.M.G., Weemaes, C., van Deuren, M., Nicolai, J., Wevers, R.A., Willemsen, M.A., Alpha-fetoprotein, a fascinating protein and biomarker in neurology. Eur. J. Paediatr. Neurol. 18 (2014), 243–248, 10.1016/j.ejpn.2013.09.003.
18. [18] Bruix, J., Sherman, M., Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022, 10.1002/hep.24199.
19. [19] EASL-EORTC, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56 (2012), 908–943.
20. [20] Omata, M., Lesmana, L.A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J.M., Choi, B.I., Poon, R.T.P., Shiina, S., Cheng, A.L., Jia, J.-D., Obi, S., Han, K.H., Jafri, W., Chow, P., Lim, S.G., Chawla, Y.K., Budihusodo, U., Gani, R.A., Lesmana, C.R., Putranto, T.A., Liaw, Y.F., Sarin, S.K., Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol. Int. 4 (2010), 439–474, 10.1007/s12072-010-9165-7.
21. [21] Chang, T.-S., Wu, Y.-C., Tung, S.-Y., Wei, K.-L., Hsieh, Y.-Y., Huang, H.-C., Chen, W.-M., Shen, C.-H., Lu, C.-H., Wu, C.-S., Tsai, Y.-H., Huang, Y.-H., Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am. J. Gastroenterol. 110 (2015), 836–844, 10.1038/ajg.2015.100.
22. [22] Marrero, J.A., Feng, Z., Wang, Y., Nguyen, M.H., Befeler, A.S., Roberts, L.R., Reddy, K.R., Harnois, D., Llovet, J.M., Normolle, D., Dalhgren, J., Chia, D., Lok, A.S., Wagner, P.D., Srivastava, S., Schwartz, M., α-Fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137 (2009), 110–118, 10.1053/j.gastro.2009.04.005.
23. [23] Lok, A.S., Sterling, R.K., Everhart, J.E., Wright, E.C., Hoefs, J.C., Di Bisceglie, A.M., Morgan, T.R., Kim, H.-Y., Lee, W.M., Bonkovsky, H.L., Dienstag, J.L., HALT-C Trial Group, Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138 (2010), 493–502, 10.1053/j.gastro.2009.10.031.
24. [24] Durazo, F.A., Blatt, L.M., Corey, W.G., Lin, J.-H., Han, S., Saab, S., Busuttil, R.W., Tong, M.J., Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 23 (2008), 1541–1548, 10.1111/j.1440-1746.2008.05395.x.
25. [25] Poté, N., Cauchy, F., Albuquerque, M., Voitot, H., Belghiti, J., Castera, L., Puy, H., Bedossa, P., Paradis, V., Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J. Hepatol. 62 (2015), 848–854, 10.1016/j.jhep.2014.11.005.
26. [26] Li, C., Zhang, Z., Zhang, P., Liu, J., Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol. Res. 44 (2014), E11–E25, 10.1111/hepr.12201.
27. [27] Yi, X., Yu, S., Bao, Y., Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin. Chim. Acta 425 (2013), 212–220, 10.1016/j.cca.2013.08.005.
28. [28] Caviglia, G.P., Abate, M.L., Petrini, E., Gaia, S., Rizzetto, M., Smedile, A., Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection: highly sensitive HCC biomarkers. Hepatol. Res. 46 (2016), E130–E135, 10.1111/hepr.12544.
29. [29] Liu, C., Xiao, G.-Q., Yan, L.-N., Li, B., Jiang, L., Wen, T.-F., Wang, W.-T., Xu, M.-Q., Yang, J.-Y., Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J. Gastroenterol. 19 (2013), 1811–1819, 10.3748/wjg.v19.i11.1811.
30. [30] Peng, S.-Y., Chen, W.J., Lai, P.-L., Jeng, Y.-M., Sheu, J.-C., Hsu, H.-C., High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int. J. Cancer 112 (2004), 44–50, 10.1002/ijc.20279.
31. [31] Lu, Y., Zhu, M., Li, W., Lin, B., Dong, X., Chen, Y., Xie, X., Guo, J., Li, M., Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells. J. Cell. Mol. Med. 20 (2016), 549–558, 10.1111/jcmm.12745.
32. [32] Buszczak, M., Signer, R.A.J., Morrison, S.J., Cellular differences in protein synthesis regulate tissue homeostasis. Cell 159 (2014), 242–251, 10.1016/j.cell.2014.09.016.
33. [33] Truitt, M.L., Ruggero, D., New frontiers in translational control of the cancer genome. Nat. Rev. Cancer 16 (2016), 288–304, 10.1038/nrc.2016.27.
34. [34] Jiang, B., Wan, Z., Huang, J., Li, L., Liu, H., Fu, S., Yang, Y., Zhang, J., Yuan, S., Wang, R., Yang, Y., Gu, F., Dong, L., Pan, Z., Zhou, W., Elevated ZC3H15 increases HCC growth and predicts poor survival after surgical resection. Oncotarget, 2016, 10.18632/oncotarget.9361 (epub ahead of print).
35. [35] Duvoux, C., Roudot-Thoraval, F., Decaens, T., Pessione, F., Badran, H., Piardi, T., Francoz, C., Compagnon, P., Vanlemmens, C., Dumortier, J., Dharancy, S., Gugenheim, J., Bernard, P.-H., Adam, R., Radenne, S., Muscari, F., Conti, F., Hardwigsen, J., Pageaux, G.-P., Chazouillères, O., Salame, E., Hilleret, M.-N., Lebray, P., Abergel, A., Debette-Gratien, M., Kluger, M.D., Mallat, A., Azoulay, D., Cherqui, D., Liver Transplantation French Study Group, Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 143 (2012), 986–994, 10.1053/j.gastro.2012.05.052.
36. [36] Hong, G., Suh, K., Suh, S., Yi, N., Lee, K., Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J. Hepatol. 64 (2016), 852–859, 10.1016/j.jhep.2015.11.033.
37. [37] Ueno, M., Hayami, S., Shigekawa, Y., Kawai, M., Hirono, S., Okada, K., Tamai, H., Shingaki, N., Mori, Y., Ichinose, M., et al. Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ≤ 5 cm: cohort study based on serum HCC markers. J. Hepatol. 63 (2015), 1352–1359.
38. [38] Li, M., Li, H., Li, C., Guo, L., Liu, H., Zhou, S., Liu, X., Chen, Z., Shi, S., Wei, J., McNutt, M.A., Li, G., Cytoplasmic alpha-fetoprotein functions as a co-repressor in RA-RAR signaling to promote the growth of human hepatoma Bel 7402 cells. Cancer Lett. 285 (2009), 190–199.
39. [39] Zhu, M., Li, W., Lu, Y., Dong, X., Chen, Y., Lin, B., Xie, X., Guo, J., Li, M., Alpha fetoprotein antagonizes apoptosis induced by paclitaxel in hepatoma cells in vitro. Sci. Rep., 6, 2016, 26472.
40. [40] Tang, H., Tang, X., Liu, M., Li, X., Targeting alpha-fetoprotein represses the proliferation of hepatoma cells via regulation of the cell cycle. Clin. Chim. Acta 394 (2008), 81–88.
41. [41] Pardee, A.D., Shi, J., Butterfield, L.H., Tumor-derived α-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. J. Immunol. 193 (2014), 5723–5732, 10.4049/jimmunol.1400725.
42. [42] Li, M., Li, H., Li, C., Wang, S., Jiang, W., Liu, Z., Zhou, S., Liu, X., McNutt, M.A., Li, G., Alpha-fetoprotein: a new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines. Int. J. Cancer 128 (2011), 524–532, 10.1002/ijc.25373.
43. [43] Zhu, M., Guo, J., Xia, H., Li, W., Lu, Y., Dong, X., Chen, Y., Xie, X., Fu, S., Li, M., Alpha-fetoprotein activates AKT/mTOR signaling to promote CXCR4 expression and migration of hepatoma cells. Oncoscience 2 (2015), 59–70, 10.18632/oncoscience.115.
44. [44] Parpart, S., Roessler, S., Dong, F., Rao, V., Takai, A., Ji, J., Qin, L.-X., Ye, Q.-H., Jia, H.-L., Tang, Z.-Y., Wang, X.W., Modulation of miR-29 expression by α-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology 60 (2014), 872–883, 10.1002/hep.27200.
45. [45] Nobuoka, D., Kato, Y., Gotohda, N., Takahashi, S., Nakagohri, T., Konishi, M., Kinoshita, T., Nakatsura, T., Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol. Rep. 24 (2010), 521–528.
46. [46] Shim, J.H., Han, S., Lee, Y.-J., Lee, S.-G., Kim, K.M., Lim, Y.-S., Chung, Y.-H., Lee, Y.S., Lee, H.C., Half-life of serum alpha-fetoprotein: an early prognostic index of recurrence and survival after hepatic resection for hepatocellular carcinoma. Ann. Surg. 257 (2013), 708–717, 10.1097/SLA.0b013e318273be70.
47. [47] Liu, G., Wang, K., Li, J., Xia, Y., Lu, L., Wan, X., Yan, Z., Shi, L., Lau, W.Y., Wu, M., Shen, F., Changes in serum alpha fetoprotein in patients with recurrent hepatocellular carcinoma following hepatectomy. J. Gastroenterol. Hepatol. 30 (2015), 1405–1411, 10.1111/jgh.12953.
48. [48] Toyoda, H., Kumada, T., Tada, T., Ito, T., Maeda, A., Kaneoka, Y., Kagebayashi, C., Satomura, S., Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy. Cancer Med. 3 (2014), 643–651, 10.1002/cam4.218.
49. [49] Jin, J., Niu, X., Zou, L., Li, L., Li, S., Han, J., Zhang, P., Song, J., Xiao, F., AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood samples is a pivotal predictive marker for metastasis. Cancer Lett. 378 (2016), 33–37, 10.1016/j.canlet.2016.04.033.
50. [50] Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J.S., Luo, R., Feng, J., Ye, S., Yang, T.-S., Xu, J., Sun, Y., Liang, H., Liu, J., Wang, J., Tak, W.Y., Pan, H., Burock, K., Zou, J., Voliotis, D., Guan, Z., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10 (2009), 25–34, 10.1016/S1470-2045(08)70285-7.
51. [51] Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A.C., Santoro, A., Raoul, J.-L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T.F., Galle, P.R., Seitz, J.-F., Borbath, I., Häussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., Bruix, J., SHARP Investigators Study Group, Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359 (2008), 378–390, 10.1056/NEJMoa0708857.
52. [52] Personeni, N., Bozzarelli, S., Pressiani, T., Rimassa, L., Tronconi, M.C., Sclafani, F., Carnaghi, C., Pedicini, V., Giordano, L., Santoro, A., Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J. Hepatol. 57 (2012), 101–107, 10.1016/j.jhep.2012.02.016.
53. [53] Nakazawa, T., Hidaka, H., Takada, J., Okuwaki, Y., Tanaka, Y., Watanabe, M., Shibuya, A., Minamino, T., Kokubu, S., Koizumi, W., Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur. J. Gastroenterol. Hepatol. 25 (2013), 683–689, 10.1097/MEG.0b013e32835d913b.
54. [54] Houessinon, A., Gicquel, A., Bochereau, F., Louandre, C., Nyga, R., Godin, C., Degonville, J., Fournier, E., Saidak, Z., Drullion, C., Barbare, J.-C., Chauffert, B., François, C., Pluquet, O., Galmiche, A., Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib. Cancer Lett. 370 (2016), 242–249, 10.1016/j.canlet.2015.10.032.
55. [55] Hetz, C., Chevet, E., Oakes, S.A., Proteostasis control by the unfolded protein response. Nat. Cell Biol. 17 (2015), 829–838, 10.1038/ncb3184.
56. + ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol. Cancer Ther. 11 (2012), 2610–2620, 10.1158/1535-7163.MCT-12-0516.
57. [57] Maurel, M., Chevet, E., Tavernier, J., Gerlo, S., Getting RIDD of RNA: IRE1 in cell fate regulation. Trends Biochem. Sci. 39 (2014), 245–254, 10.1016/j.tibs.2014.02.008.
58. [58] Galmiche, A., Sauzay, C., Houessinon, A., Chauffert, B., Pluquet, O., Probing tumour proteostasis and the UPR with serum markers. Trends Cancer 2 (2016), 219–221, 10.1016/j.trecan.2016.04.004.
59. [59] Urra, H., Dufey, E., Avril, T., Chevet, E., Hetz, C., Endoplasmic reticulum stress and the hallmarks of cancer. Trends Cancer 2 (2016), 252–262.
60. [60] Sherman, M., The resurrection of alphafetoprotein. J. Hepatol. 52 (2010), 939–940, 10.1016/j.jhep.2010.02.006.